NCT05996627View on ClinicalTrials.gov

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Belumosudil

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Electronic Health Record Review

Ancillary studies

DRUG

Placebo Administration

Given PO

Trial Locations (4)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT05996627 - Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter